Gurkamal S. Chatta

Gurkamal S. Chatta

Auto-generated profile, based on publicly available information

Gurkamal S. Chatta

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DPDaniel Peter Petrylak
Daniel Peter Petrylak
NVNicholas J. Vogelzang
Nicholas J. Vogelzang
GCGurkamal S. Chatta
Gurkamal S. Chatta
MFMark T. Fleming
Mark T. Fleming
DSDavid C. Smith
David C. Smith
RIRobert Joseph Israel
Robert Joseph Israel
144 Background: PSMA is a validated target that is overexpressed selectively on prostate cancer cells. PSMA ADC is a fully human IgG1 antibody conjugated to the microtubule disrupting agent MMAE which binds to PSMA-positive cells, inducing cytotoxicity. A phase 1 study showed activity and tolerability at doses from 1.8-2.5 mg/kg. We have enrolled 119 mCRPC pts who progressed following abi/enz in a phase 2 trial of PSMA ADC. Methods: mCRPC pts (83 taxane experienced (TE) and 36 chemo-naïve (CN)) were administered PSMA ADC 2.5 or 2.3 mg/kg IV Q3 wk for up to 8 cycles. 95% of pts received prior abi and/or enz treatment. Safety, antitumor activity (including PSA, CTCs, and tumor imaging) and exploratory biomarkers were assessed. Results: In all treated pts, PSA declines of ≥30% and ≥50% were 30% and 14%, respectively (n=113); CTC counts showed a decline of ≥50% in 78% of pts and conversion from ≥5 to <5 cells/7.5 ml blood in 47% (n=77) at any time during the study. For 2.3 mg/kg pts (n=82), corresponding PSA declines were 35% and 17%; CTC declines of ≥50% were seen in 81% and conversions in 46% (n=54). For CN pts, PSA declines of ≥30% and ≥50% were 31% and 20% (n=35); CTC declines of ≥50% were seen in 89% and conversion in 53% (n=19). Radiologic response by RECIST in 31 pts with measurable target lesions: PR in 4 pts, SD in 19 pts, and PD in 8 pts. Efficacy responses were associated with: low neuroendocrine serum markers (low CgA, low NSE, and high PSA), high PSMA expression (CTCs or tumor tissue). The most common treatment-related AEs ≥CTCAE grade 3 were neutropenia (TE: 25%; CN: 22%), fatigue (20%; 8%), electrolyte imbalance (16%; 11%), anemia (10%; 8%), and neuropathy (8%; 8%). Grade 1-2 neuropathy occurred in 40% (TE) and 50% (CN) of pts. Two 2.5 mg/kg pts (n=34) and one 2.3 mg/kg pt (n=85) died of sepsis. 2.3 mg/kg was better tolerated than 2.5 mg/kg. Conclusions: PSMA ADC was active in abi/enz refractory mCRPC pts. Clinically significant AEs included neutropenia and neuropathy. CTC conversions/reductions, PSA declines, and radiologic evidence of antitumor activity were seen in CN as well as heavily pretreated pts. Clinical trial information: NCT01695044.

22 November 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
RSRandy F. Sweis
Randy F. Sweis
GCGurkamal S. Chatta
Gurkamal S. Chatta
RJRohit K. Jain
Rohit K. Jain
HMHelen Moon
Helen Moon
SDScott Edward Delacroix
Scott Edward Delacroix
EYEvan Y. Yu
Evan Y. Yu
Purpose: Advanced urothelial cancer generally has high mortality despite modern anti–PD-1/L1 antibody–based combinations. Augmenting checkpoint inhibitor–mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (Cancer Immunotherapy Trials Network-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses. Patients and Methods: Patients with urothelial cancer after platinum chemotherapy were randomized to atezolizumab alone or with CYT107 weekly for four doses. The primary objective was clinical efficacy by the objective response rate (ORR). Secondary objectives included safety, toxicity, and other clinical outcomes. Correlative endpoints included peripheral immunophenotyping and quantification of cytokines. Results: CYT107 plus atezolizumab was well-tolerated, without dose-limiting toxicities and lower grade 3 to 4 treatment-related adverse events compared with atezolizumab monotherapy. The ORR was 26.3% for the combination therapy versus 23.8% for atezolizumab alone (P = 0.428). The complete response rate was 10.5% for the combination therapy versus 4.8% for monotherapy. Three patients on combination therapy had responses >21 months versus one with monotherapy. CD4+ and CD8+ T-lymphocyte expansion occurred in patients with response to combination therapy, with the greatest effect in T memory stem cells. Patients who responded to treatment exhibited elevated baseline levels of CCL4 and reduced levels of VEGFA and TNF. Conclusions: Combining CYT107 with atezolizumab was safe and resulted in lymphocyte expansion, a doubling of the complete response rate, and durable responses exceeding 2 years. However, the ORR was similar to atezolizumab alone. Increased and sustained doses of CYT107 coupled with patient selection strategies should be further investigated.

17 January 2025
Verified
Other
Open access
RSRandy F. Sweis
Randy F. Sweis
GCGurkamal S. Chatta
Gurkamal S. Chatta
RJRohit K. Jain
Rohit K. Jain
HMHelen Moon
Helen Moon
SDScott Edward Delacroix
Scott Edward Delacroix
EYEvan Y. Yu
Evan Y. Yu
Kaplan-Meier Curve for Overall Survival - All Randomized Subjects.

17 January 2025
Verified
Other
Open access
RSRandy F. Sweis
Randy F. Sweis
GCGurkamal S. Chatta
Gurkamal S. Chatta
RJRohit K. Jain
Rohit K. Jain
HMHelen Moon
Helen Moon
SDScott Edward Delacroix
Scott Edward Delacroix
EYEvan Y. Yu
Evan Y. Yu
Cytokine changes between C1D1 and C2D1 in the experimental arm.

17 January 2025
Verified
Other
Open access
RSRandy F. Sweis
Randy F. Sweis
GCGurkamal S. Chatta
Gurkamal S. Chatta
RJRohit K. Jain
Rohit K. Jain
HMHelen Moon
Helen Moon
SDScott Edward Delacroix
Scott Edward Delacroix
EYEvan Y. Yu
Evan Y. Yu
Pharmacodynamics showing fold-change from baseline of % of T lymphocyte memory subsets for (A,C) CD4+ T cells and (B,D) CD8+ T cells. Tscm lymphocyte subset the most highly significantly expanded T cell subset for both CD4+ and CD8+ T cells and seen only in (A,B) experimental arm and not (C,D) control arm subjects. (E,F) CX3CR1 expression in CD4+ Tscm lymphocytes trended lower in responding patients. T lymphocytes were evaluated and analyzed by 14-color flow cytometry on cryopreserved PBMCs. TE = Terminal Effector, EM = Effector Memory, CM = Central Memory. N = Naïve, SCM = T memory Stem Cells.

17 January 2025
Verified
Other
Open access
RSRandy F. Sweis
Randy F. Sweis
GCGurkamal S. Chatta
Gurkamal S. Chatta
RJRohit K. Jain
Rohit K. Jain
HMHelen Moon
Helen Moon
SDScott Edward Delacroix
Scott Edward Delacroix
EYEvan Y. Yu
Evan Y. Yu
Purpose:Advanced urothelial cancer generally has high mortality despite modern anti–PD-1/L1 antibody–based combinations. Augmenting checkpoint inhibitor–mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase II study (Cancer Immunotherapy Trials Network-14) in 47 patients to explore whether human recombinant IL-7 (CYT107) could be safely combined with PD-L1 inhibition to enhance responses.Patients and Methods:Patients with urothelial cancer after platinum chemotherapy were randomized to atezolizumab alone or with CYT107 weekly for four doses. The primary objective was clinical efficacy by the objective response rate (ORR). Secondary objectives included safety, toxicity, and other clinical outcomes. Correlative endpoints included peripheral immunophenotyping and quantification of cytokines.Results:CYT107 plus atezolizumab was well-tolerated, without dose-limiting toxicities and lower grade 3 to 4 treatment-related adverse events compared with atezolizumab monotherapy. The ORR was 26.3% for the combination therapy versus 23.8% for atezolizumab alone (P = 0.428). The complete response rate was 10.5% for the combination therapy versus 4.8% for monotherapy. Three patients on combination therapy had responses >21 months versus one with monotherapy. CD4+ and CD8+ T-lymphocyte expansion occurred in patients with response to combination therapy, with the greatest effect in T memory stem cells. Patients who responded to treatment exhibited elevated baseline levels of CCL4 and reduced levels of VEGFA and TNF.Conclusions:Combining CYT107 with atezolizumab was safe and resulted in lymphocyte expansion, a doubling of the complete response rate, and durable responses exceeding 2 years. However, the ORR was similar to atezolizumab alone. Increased and sustained doses of CYT107 coupled with patient selection strategies should be further investigated.